Furthermore, multicenter studies are warranted to validate these findings and to better stratify future AML therapies, and after that it should be considered that whether PARP10 expression could be included into the novel ELN 2022 AML prognostic recommendations. This evidence concerns the gene PARP10 and acute myeloid leukemia.